Olanzapine News and Research

RSS

Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.

Genes play a key role in stress response

Both nature and nurture - genetic makeup and the environment experienced through life - combine to influence health and well-being, Duke University Medical Center researchers and their colleagues have determined in four new studies.

7 Mar 2006

Study of the effects of aripiprazole, olanzapine, quetiapine and risperidone, in elderly patients with dementia

Some newer antipsychotic medications may be associated with a small increased risk of death when used to treat elderly dementia patients, psychiatrists at Johns Hopkins warn.

18 Oct 2005

Atypical antipsychotic drugs slightly increase risk for death when used in people with dementia

Atypical antipsychotic drugs seem to confer a small increased risk for death when used in people with dementia, concludes a team of researchers from the Keck School of Medicine of the University of Southern California in a meta-analysis of 15 clinical trials published in the October 19 issue of the JAMA: The Journal of the American Medical Association.

18 Oct 2005

New study details side effects of five medications that are currently used to treat people with schizophrenia

A large study funded by NIH's National Institute of Mental Health (NIMH) provides, for the first time, detailed information comparing the effectiveness and side effects of five medications - both new and older medications - that are currently used to treat people with schizophrenia.

21 Sep 2005

FDA issues public health advisory for antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.”

12 Apr 2005

FDA wants warnings put on antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of “atypical antipsychotic drugs.”

11 Apr 2005

New antipsychotic drug prevents brain loss in schizophrenia

A new brain imaging study of recently diagnosed schizophrenia patients has found, for the first time, that the loss of gray matter typically experienced by patients can be prevented by one of the new atypical antipsychotic drugs, olanzapine, but not by haloperidol, an older, conventional drug.

4 Apr 2005

Different antipsychotic medications may have different effects on brain volume in patients with first episode of psychosis

After a first psychotic episode, patients who were treated with an atypical antipsychotic medication had less change in brain volume compared with patients treated with a conventional antipsychotic medication, according to an article in the April issue of Archives of General Psychiatry.

4 Apr 2005

Quetiapine speeds up rate of decline in Alzheimers

Quetiapine, a drug commonly used in nursing homes to treat agitation and related symptoms in people with Alzheimers' disease actually worsens patients' illness, speeding up their rate of decline significantly, says a paper published on bmj.com.

20 Feb 2005

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

The antidepressant Cymbalta (duloxetine HCl), a dual-reuptake inhibitor of serotonin and norepinephrine, 60 mg once or twice daily, significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression, according to 12-week data presented at the annual meeting of the American College of Rheumatology.

18 Oct 2004

Drug used to treat schizophrenia and other psychotic disorders appears effective at treating Alzheimer’s disease

Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer’s disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.

23 Jul 2004

Researchers find next generation of medications to help schizophrenics

Researchers at Duke University Medical Center have found that a new generation of medications called "atypical antipsychotics" can significantly lower the risk of violent behavior in people with schizophrenia who are being treated in community-based centers.

13 Apr 2004

FDA has approved Zyprexa, injectable anti-psychotic drug

Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.

30 Mar 2004